OncoCyte Corporation (OCX) is a molecular diagnostics company that develops and commercializes innovative tests to detect cancer at an early stage. The company's lead product, DetermaVu, is a non-invasive liquid biopsy test that uses RNA sequencing technology to identify lung cancer at an early stage, when it is most treatable. OncoCyte is also developing other diagnostic tests to detect various types of cancer, including breast and bladder cancer. The company is headquartered in Irvine, California, and as of September 2021, had a market capitalization of approximately $380 million.
OncoCyte Corporation (OCX) is a molecular diagnostics company that develops and commercializes innovative tests to detect cancer at an early stage. The company's lead product, DetermaVu, is a non-invasive liquid biopsy test that uses RNA sequencing technology to identify lung cancer at an early stage, when it is most treatable. OncoCyte is also developing other diagnostic tests to detect various types of cancer, including breast and bladder cancer. The company is headquartered in Irvine, California, and as of September 2021, had a market capitalization of approximately $380 million.